Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, tells us about outcomes from the long-term follow up of Checkmate-004 in metastatic melanoma

Tags: ASCO Conference CoverageMelanoma (includes BCC)

Published: 10 June 2019

Recent Videos: Melanoma (includes BCC)

video

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

Related Videos

video-image

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

video-image

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

video-image

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

video-image

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

video-image

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

video-image

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Che-Kai Tsao, MD, discusses the current application of biomarkers in renal cell carcinoma

video-image

Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019

video-image

Parameswaran Hari, MD, speculates on whether KRD will replace stem cell transplant

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

video-image

Che-Kai Tsao, MD, on deciding between I-O + TKIs combinations indicated for the treatment of RCC

video-image

Philip Philip MD, PhD, FRCP, on the APACT trial in surgically resected pancreatic adenocarcinoma

video-image

Sandip Patel, MD, describes the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Lowell L. Hart, MD, FACP, explains the mechanism of action for trilaciclib

video-image

Parameswaran Hari, MD, discusses the role of CAR-T therapy in multiple myeloma

video-image

Shirish Madhav Gadgeel, MBBS, offers opinion on the results of the RELAY trial from ASCO 2019

video-image

Josep Tabernero, MD, PhD, speculates on exciting clinical trial outcomes in gastric cancer

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Lowell L. Hart, MD, FACP, regarding recent data investigating trilaciclib in SCLC

video-image

Parameswaran Hari, MD, considers whether isatuximab will become a viable option in MM

video-image

Shirish Madhav Gadgeel, MBBS, on the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinoma

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Nancy A. Dawson, MD, regarding preferred agents in the 2nd line setting in renal cell carcinoma

video-image

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

video-image

Michael B. Atkins, MD, on the role of IMDC classification in treatment decision-making

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

video-image

Marwan G. Fakih, MD, on whether KRAS amplification predicts resistance to EGFR therapies

video-image

Nancy A. Dawson, MD, on selecting the appropriate I-O + TKI combo in the treatment of 1st line RCC

video-image

Vincent Chung, MD, shares details from the APACT study in pancreatic adenocarcinoma

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

video-image

Michael B. Atkins, MD, comments on clinical trials investigating the use of I-O and TKIs in RCC

video-image

Saad Usmani, MD, FACP, regarding outcomes from the MAIA study presented at ASCO 2019

video-image

Che-Kai Tsao, MD, considers the various I-O and TKI combinations available for 1st line RCC

video-image

Josep Tabernero, MD, PhD, provides perspective on the POLO trial in pancreatic

video-image

Philip Philip MD, PhD, FRCP, on BRCA gene mutations & outcomes in pancreatic cancer

video-image

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Kristin Higgins, MD, offers opinion on the PACIFIC study in non-small cell lung cancer

video-image

Parameswaran Hari, MD, considers the implications of the CASSIOPEIA trial

video-image

Marwan G. Fakih, MD, regarding outcomes from the AMG 510 study

video-image

Shirish Madhav Gadgeel, MBBS, on treating non-squamous NSCLC patients expressing high PD-L1

video-image

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Vincent Chung, MD, elaborates on BRCA mutations and pancreatic cancer

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

video-image

Michael B. Atkins, MD, considers preferred agents in the treatment of RCC in the 2nd line

video-image

Saad Usmani, MD, FACP, compares IV daratumumab and subcutaneous daratumumab

video-image

Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC

video-image

Josep Tabernero, MD, PhD, offers perspective on Keynote-062 in advanced gastroesophageal

video-image

Philip Philip MD, PhD, FRCP, discusses outcomes from the POLO trial in pancreatic cancer

video-image

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019

video-image

Kristin Higgins, MD, shares her interpretation of the PACIFIC study in unresectable NSCLC

video-image

Parameswaran Hari, MD, elaborates on the outcome from the ECOG trial in SMM

video-image

Shirish Madhav Gadgeel, MBBS, regarding the top stories in lung cancer from ASCO 2019

video-image

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

Vincent Chung, MD, shares outcomes from the POLO trial metastatic pancreatic cancer

video-image

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

video-image

Michael B. Atkins, MD, on selecting I-O and TKI combinations for the treatment of 1st line RCC

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Andre Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Robert M. Rifkin, MD, FACP, speculates on the promise of bispecific antibodies in MM

video-image

Andre Goy, MD, shares the most exciting advances in lymphoma coming out of ASCO 2019

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debra Patt, MD, MPH, MBA, outlines policies proposed to address drug pricing

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Robert M. Rifkin, MD, FACP, discusses maintenance regimens for multiple myeloma

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debra Patt, MD, MPH, MBA, considers the transition from volume to value in the oncology space

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Thomas A. Abrams, MD, outlines next steps if an HCC patient fails 1st line therapy with I-O

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Paul G. Richardson, MD, shares clinical results from the ECOG trial in smoldering MM

video-image

Debra Patt, MD, MPH, MBA, on the factors influencing cost in novel therapeutic interventions

video-image

Leonard Saltz, MD, shares outcomes from the APACT trial in pancreatic adenocarcinoma

video-image

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab

video-image

Paul G. Richardson, MD, considers whether isatuximab shows promise as a treatment option for MM

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Talia Golan, MD, explains the role of biomarkers in the treatment of pancreatic cancer

video-image

Thomas A. Abrams, MD, offers thoughts on Keynote-062 in gastric/gastroesophageal cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab

video-image

Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Talia Golan, MD, regarding the practice-changing potential of the POLO trial

video-image

Thomas A. Abrams, MD, elaborates on the outcomes from the APACT study

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC

video-image

Robert M. Rifkin, MD, FACP, discusses outcomes from the ECOG trial in smoldering multiple myeloma

video-image

Paul G. Richardson, MD, regarding the updated FORTE trial data in multiple myeloma

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Talia Golan, MD, elaborates on the outcomes from the POLO study presented at ASCO 2019

video-image

Thomas A. Abrams, MD, provides perspective on the POLO trial in metastatic pancreatic cancer

video-image

Naiyer Rizvi, MD, speculates on the future of drug development in NSCLC

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

Naiyer Rizvi, MD, offers thoughts on the role of blood TMB vs. tissue TMB

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

video-image

Naiyer Rizvi, MD, describes the role of PD-L1 & TMB biomarkers in the treatment of lung cancer

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

Andrew Goy, MD, explains how the approval of lenalidomide will impact the management of FL & MZL

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

video-image

Naiyer Rizvi, MD, tells us about the results of Keynote-001 in NSCLC

video-image

William Oh, MD, shares the differences between the ENZAMET and TITAN studies

video-image

Andrew Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

video-image

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Andrew Goy, MD, elaborates on the most exciting recent clinical advances in lymphoma

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

video-image

Bradley McGregor, MD, considers strategies for treating 2nd line RCC patients

video-image

Ravi Salgia, MD, PhD, considers the unmet medical needs in the treatment of NSCLC

video-image

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

video-image

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

video-image

Lori A. Leslie, MD, on the recent data regarding umbralisib in relapsed/refractory lymphoma

video-image

Lori A. Leslie, MD, speculates on how CAR-T cell therapy may be combined to treat lymphomas

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

video-image

Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC

video-image

Ravi Salgia, MD, PhD, offers strategies for identifying PD-L1 status

video-image

Danny Rischin, MD, MBBS, FRACP, shares updated data from ASCO '19 investigating cemiplimab in cSCC

video-image

Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting

video-image

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

video-image

Danny Rischin, MD, MBBS, FRACP, on the importance of the stratification by PD-L1 score

video-image

Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients

video-image

Ravi Salgia, MD, PhD, comments on germline mutations & the impact on NSCLC patients

video-image

Danny Rischin, MD, MBBS, FRACP, shares thoughts on Keynote-048 presented at ASCO 2019

video-image

Bradley McGregor, MD, considers the optimal approach to treating newly diagnosed RCC patients

video-image

Richard S. Finn, MD, speculates on the next phase of HCC management and research

video-image

Imane El Dika, MD, outlines next steps if an HCC patient fails 1st line therapy

video-image

Edward B. Garon, MD, on the implications of Keynote-189

video-image

Richard S. Finn, MD, outlines the next steps if an HCC patient fails 1st line therapy

video-image

Imane El Dika, MD, considers the role of I-O in the management of HCC

video-image

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

video-image

Richard S. Finn, MD, offers opinion on the broader role of I-O in the management of HCC

video-image

Imane El Dika, MD, elaborates on the outcomes of Keynote-240 presented at ASCO 2019

video-image

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

video-image

Richard S. Finn, MD, regarding outcomes from Keynote-240 in 1st line HCC

video-image

Pasi A. Jänne, MD, PhD, regarding the unmet medical needs in the treatment of NSCLC

video-image

Daneng Li, MD, elaborates on the COSMIC-312 trial in hepatocellular carcinoma

video-image

Pasi A. Jänne, MD, PhD, discusses some of the challenges in managing NSCLC

video-image

Martin E. Gutierrez, MD, discusses some of the top challenges in managing NSCLC

video-image

Daneng Li, MD, describes next steps if an HCC patient fails 1st line I-O therapy

video-image

Bruce Feinberg, DO, speculates on the future of AI in oncology treatment centers

video-image

Amrita Krishnan, MD, considers whether KRD will replace stem cell transplant

video-image

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda

video-image

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

video-image

Bruce Feinberg, DO, outlines some of the concerns that oncologists have regarding AI

video-image

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

video-image

Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM

video-image

Pasi A. Jänne, MD, PhD, elaborates on outcomes from the RELAY trial

video-image

Martin E. Gutierrez, MD, discusses the implications of the RELAY trial from ASCO 2019

video-image

Bruce Feinberg, DO, on how AI may evolve as a clinical decision-making support tool

video-image

Amrita Krishnan, MD, regarding outcomes from the CASSIOPEIA trial presented at ASCO '19

video-image

Pasi A. Jänne, MD, PhD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Martin E. Gutierrez, MD, regarding the implications of the initial & updated results of Keynote-189

video-image

Bruce Feinberg, DO, on real-world examples of artificial intelligence applications in oncology

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Daneng Li, MD, considers the role of immuno-oncology in the management of HCC

video-image

Pasi A. Jänne, MD, PhD, on molecular testing prior to the treatment of advanced NSCLC

video-image

Martin E. Gutierrez, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Bruce Feinberg, DO, defines and considers artificial intelligence as a healthcare tool

video-image

Pasi A. Jänne, MD, PhD, on the study of U3-1402 in EGFR mutant NSCLC presented at ASCO 2019

video-image

Daneng Li, MD, tells us about the outcomes of Keynote 240 presented at ASCO 2019

video-image

Bradley McGregor, MD, on combo ipilimumab + nivolumab in variant histologies of bladder cancer

video-image

Lori A. Leslie, MD, on how CAR-T cell therapy has impacted the treatment of B-cell lymphomas

video-image

Kim Chi, MD, regarding the differences in design between the ENZAMET & TITAN studies

video-image

Tian Zhang, MD, on promising studies in sarcomatoid RCC & urothelial cancer from ASCO '19

video-image

Martin E. Gutierrez, MD, on the role of clinico-genomic data sharing in lung cancer treatment

video-image

Pasi A. Jänne, MD, PhD, on advances in the treatment of lung cancer being presented at ASCO 2019

video-image

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

video-image

Bruce Feinberg, DO, considers how artificial intelligence may help practices become more efficient

video-image

Tian Zhang, MD, shares thoughts on the PDIGREE trial in metastatic, untreated RCC

video-image

Bradley McGregor, MD, on the data regarding enfortumab in post-platinum + I-O bladder cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing

video-image

Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database

video-image

Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database

video-image

Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer

video-image

John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer

video-image

James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer

video-image

James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma

video-image

James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer

video-image

James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018

video-image

Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments

video-image

Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement

video-image

Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval

video-image

Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars

video-image

Ivo Abraham, PhD, RN, explains the key features of a biosimilar

video-image

Randall A. Oyer, MD, considers the work being done to address disparities in healthcare

video-image

Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405

video-image

Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer

video-image

Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer

video-image

Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study

video-image

Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

George Simon, MD, FACP, FCCP, on the Checkmate 032 & CTONG 1104 NSCLC studies presented at ASCO

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Christopher Logothetis, MD, offers opinion on the efficacy of the AR-V7 test

video-image

Christopher Logothetis, MD, explains how he identifies the right patients for Zytiga versus Xtandi

video-image

Christopher Logothetis, MD, regarding CHAARTED, STAMPEDE, and LATITUDE data from ASCO 2017

video-image

Christopher Logothetis, MD, speculates on the cost implications of abiraterone

video-image

Christopher Logothetis, MD, on why the results of the LATITUDE study will be practice changing

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

video-image

Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Howard Hochster, MD, regarding the new peri-operative regimen FLOT for gastric cancer

video-image

Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients

video-image

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

video-image

Patricia Goldsmith discusses the tools available for cancer patients on their journey

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Nancy Dawson, MD, compares the side effect profiles of abiraterone and chemotherapy

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated

video-image

Nancy Dawson, MD, regarding the STAMPEDE study presented at ASCO 2017

video-image

Nancy Dawson, MD, shares her impressions of the LATITUDE study

video-image

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

video-image

Barbara Burtness, MD, considers whether H&N patients should be routinely tested for PD-L1

video-image

Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers

video-image

Barbara Burtness, MD, shares her thoughts on the results of the LUX head and neck 2 study

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency

video-image

Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, considers the relevance of testing for PD-L1

video-image

Jack West, MD, discusses possible immunotherapy combination treatments in the near future

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDE

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on the practice-changing results of the LATITUDE study

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

video-image

Jeff Sharman, MD, comments on emerging trends in CLL management

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, comments on the differences between CDK 4/6 inhibitors

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017

video-image

Leonard Saltz, MD, shares thoughts on how to control rising drug prices without impacting value

video-image

Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers

video-image

Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer

video-image

Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors

video-image

Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma

video-image

Daniel Petrylak, MD, on prostate cancer guidelines and the results of the LATITUDE study

video-image

Andrew Pecora, MD, FACP, CPE, shares how COTA and IBM Watson are working together

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, on establishing a more informatics enabled oncology practice

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Debra Patt, MD, MPH, MBA, comments on how she sees the new administration addressing drug costs

video-image

Debra Patt, MD, MPH, MBA, offers opinion on incorporating liquid biopsy into patient management

video-image

Debra Patt, MD, MPH, MBA, on the repercussions if utilization management isn’t used properly

video-image

Debra Patt, MD, MPH, MBA, explains the concept and importance of utilization management

video-image

Andrew Norden, MD, speculates on the future of Watson for oncology

video-image

Andrew Norden, MD, on how physicians can take advantage of Watson’s expanding library of tumor types

video-image

Andrew Norden, MD, describes the clinical utility of Watson for oncology

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC

video-image

Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO

video-image

Lyudmila Bazhenova, MD, on the progress being made towards successfully sequencing ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on differentiating between ALK inhibitors

video-image

Lyudmila Bazhenova, MD, speaks to the reliability and accuracy of ALK biomarkers

video-image

Aref Al-Kali, MD, on how hematologists will adopt midostaurin for FLT3+ AML patients

video-image

Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients

video-image

Aref Al-Kali, MD, offers perspective on treating elderly AML patients

video-image

Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC

video-image

Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Barbara Burtness, MD on the Keynote-055 study in SCCHN patients

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Tanios Bekaii-Saab, MD, on how clinicians factor economics into therapeutic decision making

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

video-image

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

video-image

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

video-image

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

video-image

Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN

video-image

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

video-image

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Laura Chow, MD tells us about products in development for SCCHN

video-image

Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers